USANA Health Sciences (USNA) Stock Price, News & Analysis

Company Overview

USANA Health Sciences, Inc. is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America. Key regions of operation include the United States, Canada, China, Taiwan, Australia, the United Kingdom and Mexico. The company leverages a multilevel marketing structure, enabling independent distributors to earn commissions on personal sales and the sales of their recruited team members.

USANA’s manufacturing facilities are located in Salt Lake City, Utah, and in Tlalnepantla, Mexico, providing global production capacity to support demand. The company has emphasized scientific validation of its products and maintains partnerships with third‐party research institutions. Through its focus on health sciences and peer‐reviewed studies, USANA positions itself as a science‐driven provider of wellness solutions.

Key Stats

• Today's Range: $17.08 to $18.22
• 50-Day Range: $16.87 to $20.69
• 52-Week Range: $16.60 to $38.32
• Volume: 124,138 shs
• Average Volume: 109,877 shs
• Market Capitalization: $335.60 million
• P/E Ratio: 38.68
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

USANA Health Sciences Stock Analysis - MarketRank™

USANA Health Sciences scored higher than 47% of companies evaluated by MarketBeat, and ranked 554th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Reduce

Consensus Rating

USANA Health Sciences has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

USANA Health Sciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 4.4 / 5
• Proj. Earnings Growth: 30.66%

Earnings Growth

Earnings for USANA Health Sciences are expected to grow by 30.66% in the coming year, from $2.12 to $2.77 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of USANA Health Sciences is 38.68, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.53.

Price to Earnings Ratio vs. Sector

The P/E ratio of USANA Health Sciences is 38.68, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.81.

Price to Earnings Growth Ratio

USANA Health Sciences has a PEG Ratio of 0.69. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

USANA Health Sciences has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.74% of the float of USANA Health Sciences has been sold short.

Short Interest Ratio / Days to Cover

USANA Health Sciences has a short interest ratio ("days to cover") of 5.33.

Change versus previous month

Short interest in USANA Health Sciences has recently increased by 5.03%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

USANA Health Sciences does not currently pay a dividend.

Dividend Growth

USANA Health Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, USANA Health Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $93,124.00 in company stock.

Percentage Held by Insiders

0.82% of the stock of USANA Health Sciences is held by insiders.

Percentage Held by Institutions

54.25% of the stock of USANA Health Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/05/2026
• Today: 5/20/2026
• AGM 2026: 5/20/2026
• Next Earnings (Estimated): 7/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Personal Products
• Current Symbol: NYSE:USNA
• CIK: 896264
• Web: www.usana.com
• Phone: (801) 954-7100
• Fax: 801-954-7300
• Employees: 1,570
• Year Founded: 1992

Profitability

• EPS (Trailing Twelve Months): $0.47
• Trailing P/E Ratio: 38.68
• Forward P/E Ratio: 8.58
• P/E Growth: 0.69
• Net Income: $10.76 million
• Net Margins: 0.96%
• Pretax Margin: 4.35%
• Return on Equity: 6.21%
• Return on Assets: 4.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.51
• Quick Ratio: 1.69

Sales & Book Value

• Annual Sales: $925.26 million
• Price / Sales: 0.36
• Cash Flow: $4.30 per share
• Price / Cash Flow: 4.23
• Book Value: $29.44 per share
• Price / Book: 0.62

Miscellaneous

• Outstanding Shares: 18,460,000
• Free Float: 18,312,000
• Market Cap: $335.60 million
• Optionable: Optionable
• Beta: 0.77